Cell Line Development Market worth $3.96 Billion by 2019, According to a New Study on ASDReports

Friday 10 October 2014, Amsterdam

This report studies the global cell line development market for the forecast period of 2014 to 2019.This market is expected to reach $3.96 billion by 2019 from$2.2 billionin 2014, and is poised to grow at a CAGR of 12.5% from 2014 to 2019.

The global cell line development market is segmented on the basis of products, type of cell lines, source of cell lines, applications, and geographies.

Based on products, the cell line development market is categorized into equipment, and media &reagents.The media and reagents segment is expected to account for a major share of the cell line development market, by product in 2014.

The media and reagents segment is further divided into serum, media, and reagents.The reagents segment is expected to account for the largest share of the cell line development market in 2014.

The cell line development market, by type is further segmented into primary cell lines, continuous cell lines, hybridomas, and recombinant cell lines. Recombinant cell lines are expected to account for a major share of the cell line development market in 2014.

On the basis of source of cell lines, the market is segmented into mammalian, insect, and amphibian. The cell lines derived from mammalian source are likely to account for the largest share of the cell line development market in 2014.

Bioproduction, tissue engineering and regenerative medicine, toxicity testing, research, and drug discovery are the key application areas of cell lines. Bioproduction is expected to account for a major share among the application areas in the cell line development market.

On the basis of geography, the market is divided into North America, Europe, Asia, and Rest of the World (RoW). Rest of the World comprises of Latin America, Pacific countries, and Africa. North America holds the largest in the cell line development market, followed by Europe and Asia. However, the Asian market is slated to grow at the highest CAGR in the coming five years and serves as a revenue pocket for cell line manufacturers.

Over the years, the demand for cell line development equipment and media and reagents is likely to increase owing to the increasing demand for monoclonal antibodies, rising vaccine production, and use of innovative technologies to develop cell lines. However, in spite of innovative technologies in the market, developing stable and authentic cell lines still remains a challenge. Increasing risk of pandemics and communicable diseases are expected to create opportunities for the development of cell lines.

Some of the major players in the global cell line development market include American Type Culture Collection (ATCC) (U.S.), Lonza Group AG (Switzerland), Thermo Fisher Scientific, Inc. (U.S.), GE Healthcare (U.K.), Sigma-Aldrich Corporation (U.S.), Selexis SA (Switzerland), European Collection of Cell Cultures (ECACC) (U.K.), Corning, Inc. (U.S.), Wuxi App Tec, Inc. (China), and Sartorious AG (Germany).